Clinical trials
Advanced Cancer clinical trials
Below are recruiting advanced cancer clinical trials, each written for real people, not researchers. We’re tracking 2,205 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06278454RecruitingPhase 1
Radioactive injection for advanced pancreatic cancer
This trial tests a new radioactive injection called NRT6008 for people with pancreatic cancer that cannot be surgically removed. It aims to see if the treatment can shrink the tumor and improve survival.
Zhengzhou, HenanAges 18–80 - NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06547840RecruitingPhase 1
Study of MOv18 IgE for ovarian, endometrial, and breast cancers with a specific marker
This trial tests a new antibody treatment called MOv18 IgE for patients with advanced ovarian, endometrial, or triple-negative breast cancers that have a protein called folate receptor alpha (FRα) on their tumor cells. The goal is to see if the treatment is safe and effective.
BristolAges 18 years+ - NCT06555588Recruiting
Supportive talk therapy for advanced cancer symptoms
This study tests a supportive talk therapy program (called Engage) delivered via video calls. It aims to help people with advanced cancer manage tough symptoms like pain, fatigue, and distress and improve daily functioning.
Durham, North CarolinaAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Little Rock, ArkansasAges 18 years+ - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT05204147RecruitingPhase 1
Radioactive antibody for CEA-making advanced cancers
This early-phase trial tests a radioactive antibody (Ac225-DOTA-M5A) that targets CEA, a protein found on many cancer cells. It's for people with advanced or metastatic cancers that produce CEA and who have no good standard treatment options left.
Duarte, CaliforniaAges 18 years+ - NCT06755359Recruiting
Radioactive implant for locally advanced pancreatic cancer
This trial tests a new treatment called DaRT, which places tiny radioactive devices directly into your pancreatic tumor. It is for people with locally advanced pancreatic cancer that has not spread, after they have already had standard chemotherapy.
BordeauxAges 18–120 - NCT06756035RecruitingPhase 1
Testing CT-95 in advanced cancers with mesothelin
This trial tests a new drug (CT-95) for advanced cancers that have a marker called mesothelin. It's an early-phase study to see if the drug is safe and effective.
Denver, ColoradoAges 18 years+ - NCT06761027RecruitingPhase 1/Phase 2
Three-drug chemo plus targeted and immune therapy for advanced pancreatic cancer
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Fuzhou, FujianAges 18–75 - NCT06765616RecruitingPhase 2
Immunotherapy with chemo and radiation for rectal cancer before surgery
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Jinan, ShandongAges 18–85 - NCT06769425RecruitingPhase 1
Combination treatment for advanced solid tumors
This trial tests a new combination treatment for people with advanced solid tumors that have not responded to standard therapy. It aims to find a safe dose and see if the combination can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06805812Recruiting
Predicting outcomes of CDK4/6 inhibitors plus hormone therapy for advanced breast cancer
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
AvianoAges 18 years+ - NCT06866782Recruiting
European study on advanced imaging for prostate cancer
This study is a European registry that collects information from men with prostate cancer who need advanced imaging (like PSMA PET/CT or MRI) to check if the cancer has spread. By joining, you help researchers learn more about how these scans improve care.
LeuvenAges 18 years+ - NCT06963723Recruiting
Screening for financial hardship in advanced cancer
This study screens people with advanced cancer for financial problems. It aims to see if catching these problems early can improve your care and well-being.
Phoenix, ArizonaAges 21 years+ - NCT06997029RecruitingPhase 1
Study of BMS-986500 for advanced solid tumors
This trial tests a new drug called BMS-986500, alone or with other treatments, for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if the drug is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT07062263RecruitingPhase 3
Trastuzumab with chemo for HER2+ bile duct cancer
This trial tests if adding trastuzumab to standard chemotherapy can help people with advanced bile duct or gallbladder cancer that tests positive for HER2. The study aims to see if the combination works better than chemotherapy alone.
Muzaffarpur, BiharAges 18–99 - NCT07080242RecruitingPhase 1
Study of a new drug for small cell lung cancer and neuroendocrine tumors
This trial tests a new drug called BL-M14D1 for people with certain types of advanced lung cancer or neuroendocrine tumors that have stopped responding to other treatments. It may be an option if your cancer has a specific marker called DLL3.
Huntsville, AlabamaAges 18 years+ - NCT07157033RecruitingPhase 1/Phase 2
Testing XER-001 with radiation for advanced pancreatic cancer
This trial tests a new way to deliver a drug called amifostine (XER-001) alongside intense radiation therapy (SBRT) for people with locally advanced pancreatic cancer that can't be surgically removed. The goal is to see if it's safe and effective at protecting healthy tissue while targeting the tumor.
Duarte, CaliforniaAges 18 years+ - NCT07238075RecruitingPhase 1
ADCX-020 for advanced or metastatic cancers
This trial tests a new drug, ADCX-020, for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets cancer cells directly and may offer a new option when other treatments have failed.
Sydney, New South WalesAges 18 years+ - NCT07524322RecruitingPhase 1
RGT-490 for Advanced Cancers With PIK3CA Mutations
This study tests a new drug called RGT-490 in patients with advanced solid tumors (cancers that have spread or cannot be removed by surgery) that have a specific genetic change called a PIK3CA mutation. The drug is designed to block a protein involved in cancer cell growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07315854RecruitingPhase 2
Immunotherapy combo plus chemo for untreated stomach cancer
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer who have not had prior treatment. It aims to see if this combination can shrink tumors and help people live longer.
Beijing, Beijing MunicipalityAges 18–80 - NCT07326137Recruiting
Pain relief and first-line treatment for advanced bile duct or pancreatic cancer
This study tests combining standard first-line cancer therapy with a nerve block to reduce pain in people with advanced bile duct or pancreatic cancer. It aims to see if this combination can improve pain control and quality of life.
Wuhan, HubeiAges Any age - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced cancer?
- Yes. Clin2 currently lists 2,205 recruiting advanced cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.